

## Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act):

### Epigenomics AG announces placement of maximal amount of convertible bonds

**Berlin, Germany, December 19, 2013** – Epigenomics AG (ISIN: DE000A1K0516) announces the successful placement of convertible bonds, which the Company's Executive Board, with approval of the Supervisory Board, resolved to offer on December 3, 2013. 25 convertible bonds with an aggregate principal amount of EUR 2,675,000.00, convertible into up to 2,675,000 shares of the Company's common stock have been placed successfully. The details of this financing have been announced by way of ad hoc notifications dated December 3 and December 13, 2013. The issuance of the convertible bonds will generate gross proceeds of EUR 2,500,000.00.

The Bonds will be convertible into 107,000 shares of Epigenomics' common stock at any time during their term against payment of a conversion premium amounting to EUR 521,090.00, equaling a conversion price of EUR 5.87. In the event of a conversion of all 25 Bonds against payment of the conversion premium, the Company may generate further gross proceeds of up to EUR 13,027,250.00. Alternatively, after August 1, 2014, each Bond will be redeemable upon request of the bondholder at its principal amount of EUR 107,000.00. Upon maturity of the Bonds or upon FDA approval of its lead product Epi proColon®, on certain conditions, Epigenomics is entitled to require mandatory conversion. The complete Terms and Conditions are available on Epigenomics' website under [www.epigenomics.com/en/news-investors/investors/convertible-bonds-2013/convertible-bonds-2013.html](http://www.epigenomics.com/en/news-investors/investors/convertible-bonds-2013/convertible-bonds-2013.html)

Epigenomics expects that the gross proceeds from the issuance of the Bonds will contribute to securing the funding of the operating business beyond the FDA approval of the Company's lead product, Epi proColon®, a blood-based test for the detection of colorectal cancer. Among others, Epigenomics, hereby, intends to fund preparatory activities for the test's introduction onto the U.S.-American market.

- End of Ad hoc -

<b>Contact Epigenomics AG</b>
Antje Zeise CIRO Manager IR   PR Epigenomics AG Phone: +49 (0) 30 24345 386 <a href="mailto:ir@epigenomics.com">ir@epigenomics.com</a> <a href="http://www.epigenomics.com">www.epigenomics.com</a>

# epigenomics

***Epigenomics' legal disclaimers.*** This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

*The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.*